Related Experiment Videos
[Treatment of arterial hypertension with calcium antagonists]
Insights
Finoptin (verapamil) and corinfar (nifedipine) effectively lower blood pressure by reducing peripheral resistance in hypertensive patients. Verapamil suits mild to moderate hypertension, while nifedipine is for severe cases and myocardial ischemia.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Essential and secondary hypertension are significant cardiovascular conditions.
- Calcium channel blockers are widely used antihypertensive agents.
Purpose of the Study:
- To evaluate the antihypertensive effects of finoptin (verapamil) and corinfar (nifedipine).
- To assess their impact on hemodynamics and ECG repolarization.
- To determine optimal therapeutic strategies for each agent.
Main Methods:
- Study involved 52 patients with essential hypertension and 48 with secondary arterial hypertension.
- Hemodynamic parameters and ECG repolarization complex were monitored.
- Antihypertensive effects of verapamil and nifedipine were analyzed.
Main Results:
- Both verapamil and nifedipine effectively reduced blood pressure by decreasing peripheral resistance.
- Verapamil demonstrated efficacy in mild to moderate hypertension monotherapy.
- Nifedipine proved effective for severe hypertension and myocardial ischemia, normalizing ECG ST segments and T waves.
Conclusions:
- Verapamil is recommended for mild to moderate essential hypertension.
- Nifedipine is suitable for severe hypertension and as a third-stage therapy.
- Nifedipine shows potential benefits for patients with electrocardiographic signs of myocardial ischemia.
Abstract:
The antihypertensive effect of finoptin (verapamil) and corinfar (nifedipin) and their impact on the hemodynamics and the repolarization complex of the ECG were studied in 52 patients with essential hypertension and 48 patients with secondary arterial hypertension. The calcium antagonists were found to effectively decrease the blood pressure by reducing the peripheral resistance. Verapamil may be recommended for the monotherapy of mild and moderate forms of arterial hypertension, whereas corinfar should be used in cases of marked hypertension and at the third stage of therapy. Patients with electrocardiographic signs of myocardial ischemia show the normalization of the ST segment and a decreased depression of T wave under the impact of corinfar.